Oppenheimer Reiterates Outperform on Gain Therapeutics, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Hartaj Singh reiterated an Outperform rating on Gain Therapeutics (NASDAQ:GANX) and maintained a $10 price target.
June 12, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Hartaj Singh reiterated an Outperform rating on Gain Therapeutics (NASDAQ:GANX) and maintained a $10 price target.
The reiteration of the Outperform rating and maintenance of the $10 price target by Oppenheimer analyst Hartaj Singh indicates a positive outlook for Gain Therapeutics (NASDAQ:GANX) in the short term. This news is likely to have a positive impact on the stock price as it shows confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100